9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 6

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Primary Objective: determine biodistribution of radiolabeled amatuximab in tumor and nontumor tissue,  Secondary objectives: determine the safety of a single IV of Indium-CHX-A amatuximab,  Pharmacokinetic and serum levels, uptake of Indium-CHX-A amatuximab

Interventions: Amatuximab,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Basic Science,

Primary Completion Date: March 2013

Completion Date: March 2013

Last  Posted Date: September 30, 2016

Location: National Cacner Institue, Bethesda, Maryland, United States

Website Link: https://ClinicalTrials.gov/show/NCT01521325

Was this article helpful?
Dislike 0